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Abstract
Background: Access flow dysfunction, often associated with stenosis, is a common
problem in hemodialysis access and may result in progression to thrombosis. Timely
identification of accesses in need of evaluation is critical to preserving a functioning
access. We hypothesized that a risk score using measurements obtained from the
Vasc-Alert surveillance device could be used to predict subsequent interventions.
Methods: Measurement of five factors over the preceding 28 days from 1.46 million
hemodialysis treatments (6163 patients) were used to develop a score associated
with interventions over the subsequent 60 days. The score was validated in a
separate dataset of 298,620 treatments (2641 patients).
Results: Interventions in arteriovenous fistulae (AVF; n = 4125) were much more
common in those with the highest score (36.2%) than in those with the lowest score
(11.0). The score also was strongly associated with interventions in patients with an
arteriovenous graft (AVG; n = 2,038; 43.2% vs. 21.1%). There was excellent agreement in the Validation datasets for AVF (OR = 2.67 comparing the highest to lowest
score) and good agreement for AVG (OR = 1.92).
Conclusions: This simple risk score based on surveillance data may be useful for prioritizing patients for physical examination and potentially early referral for intervention.
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I N T RO DU CT I O N

contributors to these costs,3 methods to avoid these adverse
outcomes are needed.

Maintaining a functioning arteriovenous (AV) access is critical to

Inadequate access blood flow is a common problem in mature AV

providing adequate dialysis clearance, reducing catheter exposure,

fistulas (AVF) and grafts (AVG), resulting in inefficient dialysis and an

and lowering the costs of care in patients on chronic hemodialysis.

inability to attain prescribed Kt/V as an indicator of adequate dialysis.4

Indeed, vascular accesses (VAs) are considered to be the “Achilles'

Hemodynamically significant stenoses may occur in the inflow, main

heel” of hemodialysis.1 Vascular access-related expenses and com-

body, or outflow of the vascular access, reducing blood flow in the

plications account for approximately 20% of hospitalizations, $2.8

access. Stenosis can occur at a single site or develop at multiple sites;

billion in healthcare costs in the US, and substantial morbidity and

these may develop concurrently or more commonly sequentially.

mortality.2 As surgical procedures and hospitalizations associated

Stenosis invariably leads to access dysfunction. Inadequate access

with attempts to maintain a functioning AV access are major

flow most often is associated with one or more underlying stenoses,5

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Seminars in Dialysis published by Wiley Periodicals LLC.
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which can cause recirculation of blood within the access site during

values are indicative of an inflow occlusion. Alerts are issued to staff

dialysis and eventually culminate as thrombosis. Thrombectomy pro-

indicating an access at risk for complication when there are three con-

cedures, however, fail to salvage between 10% and 30% of accesses,

secutive pressure readings above a predefined threshold. The efficacy

necessitating the insertion of a central venous catheter (CVC) and

of this device in identifying dysfunctional accesses is well established,

potentially the creation of a new AV access.6 Even a successful

with sensitivity of 74% and specificity of 92%.11,12 Measurement of

thrombectomy may reduce the useful life of the access. Since there

IAP is also helpful during angiography to assure all lesions have been

are a limited number of sites available for the placement of an AV

detected and corrected.13

access, protecting and extending the life of a functional AV access

While the issuance of a VAPR or AAPR alert indicates an access

should be a major goal of quality vascular access care. Given that

complication risk, there are a number of other metrics that are derived

approximately 20% of chronic hemodialysis (HD) patients using a CVC

from the Vasc-Alert results that are also indicative the potential for an

7

have exhausted all of their viable access sites, it is critical to maintain

access complication. For example, a patient on alert every week for

each functioning AV access as long as possible.1

the past month is probably more at risk than a patient with only one

Interventions, including angioplasty and access revision, may be

alert. Likewise, a patient with very high VAPR or AAPR pressures is

used to treat access flow dysfunction in an attempt to preclude

probably more at risk than a patient whose pressures are just at the

8

thrombosis and extend the useful life of the access. Early identifica-

threshold. Another risk indication is how rapidly pressures are increas-

tion of patients with a functionally restrictive access lesions is critical

ing or in some cases decreasing over time. An access with VAPR pres-

so that they can be referred for intervention in a timely manner. Clini-

sures increasing very slowly may not be at the same level of risk as an

cal indicators, such as persistent swelling of the arm, excessive post-

access with pressures increasing more rapidly. Clinical staff are trained

dialysis bleeding, inability to maintain prescribed pump speed, or a

to interpret these other more subtle indications of risk when

drop in dialysis adequacy suggest the presence of stenosis.9 However,

reviewing the Vasc-Alert reports and triaging patients for interven-

these clinical indicators are considered to be late indicators of dys-

tional referral.

function10 as the degree of stenosis has often increased to more than

We hypothesized that a simple access risk score that summarizes

50% of the vessel diameter (typically averaging >70%) by the time

these various risk indicators from the surveillance device results,

they are discovered. Furthermore, these clinical indicators have no

would be associated with subsequent interventions and could be used

objective standard that can be used as a reference to trigger a referral.

to more easily by staff (more user friendly) to prioritize patients for

An adequate physical examination can detect significant stenosis, but

evaluation and possible intervention.

such exams require a trained clinician as well as the time to perform
them, which can be limited in busy dialysis units. Methods to help
identify and prioritize patients who are at risk of complications for

2
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clinical examination and potential referral for intervention are needed
to improve access outcomes.

2.1

|

Data Sources

The Vasc-Alert vascular access surveillance technology uses treatment data collected during each dialysis session (blood pump flow to

Data were compiled separately for use as a Development dataset and

the dialyzer (Qb), venous and negative arterial pressure, and the mean

a Validation dataset. For the Development dataset, electronic data

arterial pressure (MAP)) recorded every 30 min in the medical record

records on interventions were obtained from three vascular access

to derive the inta-access pressure (IAP) at the tip of the venous nee-

centers from 2008–2018. These intervention records were linked to

dle.11 Simply put, the venous IAP is calculated by subtracting the back

the patients' Vasc-Alert results from 86 dialysis facilities that used

pressure caused by the resistance to the blood flow through the nee-

Vasc-Alert and sent their patients to these access centers. Patient

dle and tubing from the venous drip chamber recorded pressure, and

data were included only for periods during which intervention data

adjusted for the dialyzer blood flow, type of needle and tubing, and

were available for at least 6 months with no gaps. Because some

hematocrit. To normalize these calculations between dialysis sessions,

patients at a given dialysis facility may go to an access center other

the IAP is then divided by the MAP and is called the venous access

than the one from which we received data, we limited our analyses to

pressure ratio (VAPR). The Vasc-Alert technology also provides a

patients with at least one recorded intervention at the one of the

method for monitoring for issues on the arterial side by taking the

three selected access centers. As patients were not necessarily

absolute value of the pre-pump arterial pressure (PPAP) and dividing

enrolled at their first treatment or prior to their first intervention, the

it by the blood pump flow rate (Qb), which is referred to as the arterial

first intervention during the study period does not necessarily repre-

access ratio (AAPR).

sent that specific patient's or specific access's first intervention.

High VAPR values in the access are considered to be a marker for

Rather, the study data are a snapshot of time during a given patient's

outflow stenosis, whereas high AAPR values reflect inflow stenosis.

course. A separate Validation dataset was obtained from four differ-

Because Vasc-Alert calculates VAPR and AAPR for each treatment,

ent access centers supporting patients treated at a separate set of HD

trends in the access can be discerned. For example, an increase in

centers. Treatments from 2017 through 2020 were included in this

VAPR alone over time can reflect an increase in access pressure due

dataset, following the same inclusion and exclusion criteria as for the

to a growing “downstream” venous occlusion. Similarly, high AAPR

Development dataset.
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2.2

|

Measurements

2.3

|

Interventions

Vasc-Alert calculates the VAPR and AAPR in the access with each

For each HD treatment, we assessed whether an intervention was

treatment and presents these results graphically so that trends over

performed during the subsequent 60 days. This period was chosen to

time can be evident. From these results, summary metrics can be

provide staff adequate time to confirm the indication of risk by

derived such as the number of alerts over time (density), the magni-

reviewing clinical records and performing a physical examination. It

tude of venous outflow or pre-pump pressure (severity) and their rate

also provides enough lead time to make a referral. Interventions con-

of increase or decrease (slope), and whether adequate blood flow is

sidered included angioplasty, thrombectomy, atherectomy, stent

being attained (see Figure 1). The researchers identified five metrics,

placement, surgical revision, and catheter insertion. Diagnostic angio-

each of which provides a different perspective on the health of the

grams or other procedures without treatment of stenosis were not

AV access. These metrics were assessed as potential indicators of risk.

included.

They include the following:
1. The mean VAPR as a measure of venous pressure in the access.

2.4

|

Statistical analyses

Higher pressures are markers for increasing stenosis in the access.
Increasing occlusion in the access increases the risk of thrombosis.

Each HD treatment was treated as a separate observation with or

2. The slope of VAPR as an indication of how the pressure is changing

without an intervention in the subsequent 60 days. To reduce the

over time. The steeper the slope, the faster the occlusion is growing.

potential impact of autocorrelation due to repeated interventions

3. The number of alerts in the past 28 days. An alert requires three

within a single patient, only treatments prior to the first intervention

consecutive VAPR or AAPR readings above the threshold and is a

during the study period for an individual patient were included in the

well-accepted indication of access risk. The more alerts, the more

analyses.

the access is at risk.

We assessed the association of each individual metric with the

4. The mean AAPR as a measure of arterial inflow adequacy. The more

incidence of an intervention during the subsequent 60 days using

negative the pre-pump arterial needle pressure at an achieved dia-

logistic regression models. Continuous metrics (i.e., VAPR, slope of

lyzer blood pump flow, the more likely is the blood flow in the

VAPR, mean AAPR) were modeled using restricted cubic splines with

access compromised, typically due to an inflow occlusion.

5 knots at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles. Cate-

5. The number of treatments in the past 28 days in which the aver-

gorical variables (i.e., number of alerts, number of treatments with low

age blood flow rate did not achieve at least 90% of the prescribed

BFR) were modeled in grouped categories. Metrics found to be signifi-

blood flow rate (“low BFR”). Inability to achieve prescribed blood

cantly (p < 0.01) associated with subsequent interventions were

flow is known to be a clinical indication of access dysfunction.

included in the development of the score.

The mean monthly VAPR and AAPR metrics are calculated by
averaging the results from the previous 28 days. The VAPR slope is

2.5
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Score Development

calculated over the previous 28 days. Patients had to have at least
4 HD treatments with complete measurements during the 28-day

We developed the score using sequential logistic regression models.

time-period to be included in analyses.

Based on expert opinion, the metrics were included in sequential logistic regression models in the following order: mean VAPR, VAPR slope,
the number of VAPR alerts, mean AAPR, and the number of treatments
where BFR achieved was less than 90% of the prescribed rate.
We first modeled VAPR versus intervention using restricted cubic
splines, as described above. We then categorized the distribution of
mean VAPR into bins based on the shape of this curve and assigned a
number of “points” based on the strength of the association of each
bin with the odds of intervention. We next included a similar cubic
spline for VAPR slope into a model containing the categorized mean
VAPR and then categorized the distribution of VAPR slope and
assigned “points” based on the observed adjusted association. We
then included the number of alerts into a model including categories

F I G U R E 1 Graphic is displaying 6 months of venous access
pressure ratio results, which can be summarized mathematically by
breaking the graph down into its core components, that is, amount of
pressure (severity, height of the bars), number of alerts (density,
number of red bars), and the rate change over time (slope)

of both mean VAPR and VAPR slope and categorized the number of
alerts based on the observed adjusted association. We next added
mean AAPR as a continuous variable and then low pump BFR as a categorical variable. The saturated model included all five metrics. The
sum of the “points” were then categorized into a score of 1–10 based
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on the distribution of points, with approximately 2.5% of participants

3
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|

with a score of 10, 5% with a score of 9, 7.5% with a score of 8, 10%
with a score of 7, and an equal distribution of score ≤6. Separate

3.1

|

Development data

sequential models were developed to estimate associations between
these metric and interventions for upper arm fistulae, lower arm fistu-

The development dataset consisted of data for 6,163 patients from

lae, and grafts.

86 HD centers and a total of 1,457,987 dialysis treatments. This
included 980,062 treatments in 4125 patients with an AVF and
477,925 treatments in 2,038 patients with an AVG. A total of

2.6

|

Validation Process

141,041 (14.4%) of the treatments in patients with an AVF and
126,295 (26.4%) of the treatments in patients with an AVG were

The scoring system described above was then applied to the Valida-

associated with any intervention in the subsequent 60 days.

tion dataset. The same inclusion and exclusion criteria were applied,

Each of the individual metrics were strongly associated with the

the scores were calculated, and these were compared to the observed

incidence of an intervention in the subsequent 60 days (p < 0.001)

proportion of treatments with each score that was associated with an

(Figures 2 and 3). Curvilinear associations with interventions were

intervention in the subsequent 60 days. Odds ratios were calculated

observed for VAPR, VAPR slope, and AAPR.

from bivariate logistic regression models. Confidence intervals and

The proportion of treatments with an AVF associated with an

p-values accounted for the repeated measurements within patients

intervention in the subsequent 60 days varied from a low of 11.0%

through clustered analyses. All analyses were performed with Stata,

for those with a risk score of 1 to 36.2% for those with a risk

16.1 SE (www.stata.com).

score of 10 (Figure 4). This represents an odds ratio of 4.60

F I G U R E 2 Association of
individual metrics with probability
of a subsequent intervention in
the next 60 days among those
with an arteriovenous graft. Gray
columns represent the
distribution of measurements
across all observations. (A) Mean
venous access pressure ratio
(VAPR). (B) Slope of VAPR.
(C) arterial access pressure ratio
(AAPR). (D) Number of VAPR
alerts in the previous 28 days;
(E) number of treatments with
low blood flow rate in the
previous 28 days

5
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F I G U R E 3 Association of individual metrics with probability of a subsequent intervention in the next 60 days among those with an
arteriovenous fistula. Gray columns represent the distribution of measurements across all observations. (A) Mean venous access pressure ratio
(VAPR). (B) Slope of VAPR; (C) arterial access pressure ratio (AAPR); (D) number of VAPR alerts in the previous 28 days; (E) number of treatments
with low blood flow rate in the previous 28 days

(95% confidence interval [CI]: 4.03, 5.25; p < 0.001) comparing the

3.2

|

Validation data

highest to the lowest risk score. As expected, the incidence of intervention in the development data increased monotonically with higher

The Validation dataset consisted of data for 2641 patients from

risk scores. The association of a risk score with the incidence of

84 HD centers and a total of 298,610 dialysis treatments. This

intervention was similar in AVG, though the incidence of interven-

included 215,154 treatments in 1,814 patients with an AVF and

tions was higher in all categories of the score. Those treatments in

83,456 treatments in 827 patients with an AVG. A total of 36,790

the highest category had 2.81-fold higher odds of an intervention as

(17.1%) of the treatments in patients with an AVF and 16,598 (19.9%)

compared to those in the lowest category (odds ratio = 2.81

of the treatments in patients with an AVG were associated with an

[95% CI: 2.42, 3.26; p < 0.001]).

intervention in the subsequent 60 days.

6
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F I G U R E 4 The chart is
displaying the proportion of
dialysis treatments by their access
risk score (1 to 10) associated
with an intervention (angioplasty
or thrombectomy) in the
subsequent 60 days for patients
with an arteriovenous (AV) fistula
or graft

F I G U R E 5 This chart indicates the
agreement between the results in the
Development and Validation datasets
as measured by the association of each
treatment by access risk score with an
intervention in the subsequent 60 days
for patients using an arteriovenous
fistulae (AVF)

F I G U R E 6 This chart indicates the
agreement between the results in the
Development and Validation datasets as
measured by the association of each
treatment by access risk score with an
intervention in the subsequent 60 days
for patients using an arteriovenous
fistulae (AVF)

There was excellent agreement between the results in the Valida-

The association of the risk score with incidence of intervention

tion and Development datasets for AVF. The proportion of treatments

showed less agreement in AVG (Figure 6). At all levels of the score,

with an AVF associated with an intervention in the subsequent

the incidence of an intervention was lower in validation than tin

60 days varied from a low of 12.8% for those with a risk score of 1%

developmental data The overall incidence of interventions was signifi-

to 28.2% for those with a risk score of 10 (Figure 5). This represents

cantly lower in the Validation data than in the Development data

an odds ratio of 2.67 (95% CI: 2.11, 3.39; p < 0.001) comparing the

(19.9% versus 26.5%, respectively). Nonetheless, as in the develop-

highest to the lowest risk score.

mental data base, a higher risk score was monotonically associated
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with a higher incidence of intervention, ranging from 16.9% in the

Vascular access surveillance is defined as the use of a medical

lowest category to 26.2% in the highest category (OR = 1.92 [95% CI:

device to test the access for the presence of stenosis.14 There are

1.41, 2.62]).

two types of vascular access surveillance devices available for use in

Because a score is calculated for each patient's treatment, each

HD facilities to identify patients at risk of access dysfunction.15 They

score represents one data point on a continuum of access complica-

either measure the blood flow16 through the access or the pressure at

tion risk that can vary treatment to treatment. Based on only a single

the AV access needle site.11 Flow and pressure are closely related

treatment a cut-point of ≥7, for example, results in a sensitivity and

characteristics of the access. When stenosis increases to a significant

specificity of 38% and 78% for AVF and 31% and 79% for AVG.

degree, it restricts the amount of blood flowing through the access for
the venous (outflow) side, while at the same time increasing or
decreasing the pressure for an inflow lesion (arterial). Devices that

4
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DISCUSSION AND CONCLUSIONS

measure blood flow (Transonic and On-Line Flow from Fresenius) use
a reduction in blood flow as a marker for stenosis, whereas the Vasc-

Using the results from five pressure and flow-based factors that can

Alert methodology measures changes in pressures at the two dialysis

be derived for each dialysis treatment, we developed and validated a

needles as well a blood pump flow as an indicator of risk from steno-

scoring algorithm that was strongly associated with the incidence of

sis. Both flow and pressure react to the change in the patency of the

an intervention in the subsequent 60 days. While a complication may

access due to the increasing stenotic occlusion. In a sense, they are

arise at any time for an AV access, the derived access risk score effec-

measuring the same phenomenon but using two different indications

tively places each access on a continuum scale of risk, and while an

of risk, that is, when the stenosis restricts outflow, the flow decreases

AV access with a score of 1 may not be at high risk, it still could

and the pressure increases. A secondary concomitant inflow stenosis

develop complications. The algorithm was able to categorize treat-

would mask this increase but flow through the dialysis circuit would

ments with AVF into 10 risk groups, with the highest risk group hav-

still be restricted.17

ing a nearly 3-fold higher odds of an intervention compared to the

Flow-based devices require clinical staff to conduct a test directly

lowest risk group in the validation sample. The association between

on the patient's access. Both marketed devices require that the blood

the risk score and incidence of a future intervention was somewhat

flow through the needles be reversed in order to perform the test.

less strong in AVG, but still associated with 2-fold higher odds in the

Because this process requires between 15 and 30 min to complete,

validation sample. The access risk score could be useful for staff in

flow-based surveillance is usually performed relatively infrequently,

busy dialysis facilities to prioritize patients for physical examination

usually only once a month, which may not be frequent enough, partic-

and potential referral for intervention.

ularly in grafts [19}. Direct Doppler ultrasound can also be performed

The predicted incidence of intervention in the Validation dataset

and does correlate with ultrasound dilution measurements of access

was in excellent agreement with the Development dataset for AVF. In

total blood flow (Qa), but direct Doppler is not readily available and is

AVG, however, the agreement was lower. The overall incidence of

costly. Decreasing access blood flow measured by either dilution or

treatments within 60 days of an intervention for AVF also was similar

Doppler has been shown to be a reliable indicator of subsequent

(14.4% vs. 17.1% for the Validation and Development datasets,

thrombosis during a 12-week follow-up period.18 Preemptive repair

respectively), whereas the Validation dataset for AVG had a

of subclinical stenoses (angioplasty and/or open surgery) detected by

significantly lower overall incidence than the Development dataset

surveillance has been shown to increase the longevity of AVF

(26.4 vs. 19.9%, respectively). This may be due to the fact that the

accesses when compared to clinical examination alone - so called

Development and Validation datasets were sourced from different

“monitoring.”19 However, access flow (Qa) varies with systolic blood

facilities and access centers, as well as from different time periods.

pressure, age, location of the access, obesity, and diabetes. Use of a

Different protocols and technical developments might have also

single critical value of Qa as a threshold for referral in all patients may

influenced the data cohorts.

be simplistic, and the optimal threshold might vary by patient sub-

This version of the score utilized five calculated factors derived

group. This may explain the lack of widespread uptake of Qa for the

from measurements of pressures and blood flows related to an AV

surveillance of vascular access. As for AVF, observational studies

access, with each factor measuring a different aspect of the access.

using pressure measurements show a reduction in thrombosis rate in

Taken individually, each measures progression over time of an

both AVF and AVG (12,23),

access risk factor, that is, high pressures, increasing slope, and blood

The importance of PPAP, a measure of the amount of negative

flow deficiency. In a sense each factor is a different window into

pressure needed to attain the desire Qb through the arterial needle,

the current health of an access. By combining and balancing these

has only recently been “rediscovered” by others.2,5,20 Excessive nega-

various risk factors into a simple and easily understood composite

tive PPAP can lead to a decrease in the delivery of blood flow, inade-

access risk score, it not only makes it easier for clinical staff to uti-

quate dialysis, and hemolysis and in most settings is restricted to a

lize the reports but should also increase the efficacy of the medical

value of

device. This conclusion seems to be supported by clinical use of the

often disregarded in clinical practice with pressure sensors being

access risk score, but further studies are needed to confirm these

“removed” from the dialysis circuit.21 The absolute PPAP to blood

observations.

pump speed (Qb) ratio which we term AAPR may reflect dysfunction

250 mm Hg. Unfortunately, these recommendations are

8
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of the vascular access. In a retrospective analysis, of 490 hemodialysis

of such factors would most likely increase the ability to predict future

patients with an AVF, this parameter alone had a sensitivity and spec-

complications. An additional limitation is the inclusion only of patients

ificity of 61% and 73% respectively using a cut off value of 0.5 in

with at least one intervention during the study period. This was con-

predicting AVF dysfunction. Over one year of observation, AVFs with

sidered necessary to ensure we did not include any patients where

AAPR > 0.5 had lower survival and a 3.26-fold greater risk of failure.

interventions would not be documented (i.e., immortal time bias). This

Referring hemodialysis patients for elective access angiography

could have inflated the overall incidence of interventions and limited

and percutaneous transluminal angioplasty (PTA) is commonly done to

the ability to discriminate patients at relatively low risk of interven-

prevent access failure. Chan et al performed an observational mat-

tions. However, the analysis did examine periods of the patients in

ched cohort analysis among 40,132 Medicare beneficiaries receiving

the study during time periods of relatively low risk that were not

hemodialysis with a fistula or graft.21 PTA was found to be frequent

followed by a documented intervention. We also included only the

at a rate of 20.9 procedures per 100 access years. Angiography and

first intervention during the study periods for any specific patient to

PTA significantly increased access survival when compared with non-

decrease any carry over bias due to re-stenosis of the access. Exclud-

intervention.19,22,23 The greatest benefit occurs in patients whose

ing such follow-on interventions may have, conversely, limited the

accesses were “new” or those with low blood flow. Since Qb is a

ability to discriminate very high-risk patients that have repeated

function of Qa and pressure changes can detect single or multiple ste-

access issues. Strengths of the study include the large datasets, the

nosis, the current approach of an access risk score that determines

inclusion/exclusion criteria designed to minimize bias, and the inclu-

relative risk for needing an intervention within 2 months would be

sion of a validation cohort.

useful to dialysis staff.

In summary, the algorithms developed from five pressure-based

Because Vasc-Alert surveillance uses both pressure and Qb treat-

metrics automatically derived from data captured during HD treat-

ment data that is captured automatically for every treatment, staff time

ments are strongly associated with risk of subsequent interventions.

is not required to test the access. In addition, the availability of treat-

The 1 to 10 score rankings provided may be useful to clinical staff to

ment data for each dialysis session means that the access is effectively

prioritize patients for clinical evaluation and potential referral for

being tested every dialysis session. Because Vasc-Alert is a screening

interventions. It also presents an objective method for categorizing

tool and not a diagnostic test, HD facility staff are instructed to clini-

the relative risk of an access for complications, which could be quite

cally examine patients that are on alert or have a high score for addi-

useful for access-related research.

tional clinical indicators before making a referral for a preventive
intervention. While a pressure-based surveillance device does not
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require staff to conduct a test, the reports must be reviewed especially

Vasc-Alert LLC provided funding for the development of the access

for patients that are on alert with the goal of identifying patients who

risk score.

are at-risk for an access complication. Because changes in the access
can occur very quickly, Vasc-Alert issues new reports every week,

OR CID

which can make the review of individual patient reports a time-

Brad C. Astor

https://orcid.org/0000-0002-0876-0069

consuming task especially for larger dialysis facilities. Hence, the utility

John Kennedy

https://orcid.org/0000-0002-1500-6961

of a 1 to 10 access risk score to help prioritize the patients at most risk.
As an aid for prioritizing patients, Vasc-Alert has traditionally
presented the listing of patients on alert ranked by order of the
highest number of alerts in the prior 30 days. However, a ranking by
the number of alerts is not necessarily the best metric for prioritization. For example, a patient may have three or four alerts because
they are constantly on alert, but when the patient's report is reviewed,
the average VAPR pressure may be barely above the threshold and
holding steady, (no upward slope showing increasing trend of pressure). While the access may have a lot of alerts, these additional metrics indicate that the stenosis is stable and may not be at the same
level of risk as a patient with only two alerts but a very high VAPR
average or a patient with a very steep VAPR slope. While experienced
users are able to review the graphic reports and discern relatively
quickly the patients who are at the highest risk, this becomes more
difficult for a less experienced user, especially when a large number of
patients are on alert.
Limitations of this study include the lack of inclusion of other variables that may be associated with risk of complications, including
patient demographics, comorbidities, and prior interventions. Inclusion

REFERENCESCan be deleted
1. Riella MC, Roy-Chaudhury P. Vascular access in haemodialysis:
strengthening the Achilles' heel. Nat Rev Nephrol. 2013;9(6):348-357.
2. Thamer M, Lee TC, Wasse H, et al. Medicare Costs Associated With
Arteriovenous Fistulas Among US Hemodialysis Patients. Am J Kidney
Dis. 2018 Jul;72(1):10-18.
3. Manns B, Tonelli M, Yilmaz S, et al. Establishment and maintenance of
vascular access in incident hemodialysis patients: a prospective cost
analysis. JASN. 2005;16(1):201-209.
4. Sands JJ. Vascular access monitoring improves outcomes. Blood Purif.
2005;23(1):45-49.
5. Brahmbhatt A, Misra S. The biology of hemodialysis vascular access
failure. Semin Intervent Radiol. 2016;33(1):15-20.
6. MacRae JM, Dipchand C, Oliver M, et al. Arteriovenous access failure,
stenosis, and thrombosis. Can J Kidney Health Dis. 2016;3:1-11.
https://doi.org/10.1177/2054358116669126
7. Centers for Medicare & Medicaid Services. 2007 Annual Report, End
Stage Renal Disease Clinical Performance Measures Project.
Department of Health and Human Services, Centers for Medicare &
Medicaid Services, Office of Clinical Standards & Quality, Baltimore,
Maryland, December 2007.
8. Haage P, Gunther RW. Radiological intervention to maintain vascular
access. Eur J Vasc Endovasc Surg. 2006;32(1):84-89.

9

ASTOR ET AL.

9. D'Cunha PT, Besarab A. Vascular access for hemodialysis: 2004 and
beyond. Curr Opin Nephrol Hypertens. 2004;13(6):623-629.
10. Kumbar L, Karim J, Besarab A. Surveillance and monitoring of dialysis
access. Int J Nephrol. 2012;2012:649735-649739.
11. Frinak S, Zasuwa G, Dunfee T, Besarab A, Yee J. Dynamic venous
access pressure ratio test for hemodialysis access monitoring.
Am J Kidney Dis. 2002;40(4):760-768.
12. Zasuwa G, Frinak S, Besarab A, Peterson E, Yee J. Automated intravascular access pressure surveillance reduces thrombosis rates. Semin
Dial. 2010;23(5):527-535.
13. Asif A, Besarab A, Gadalean F, Merrill D, Rismeyer AE, Contreras G,
Leclercq B, Lenz O, Wallach J, Wallach J, Levine MI. Utility of static
pressure ratio recording during angioplasty of arteriovenous graft stenosis. Semin Dial. 2006 Nov-Dec;19(6):551–556. https://doi.org/10.
1111/j.1525-139X.2006.00221.x. PMID: 17150059.
14. National Kidney Foundation K/DOQI. Clinical practice guideline and
clinical practice recommendations for vascular access 2006.
Am J Kidney Dis. 2006;48(suppl 1):S176-S273.
15. Besarab A. Access monitoring is worthwhile and valuable. Blood Purif.
2006;24(1):77-89.
16. Salman L, Rizvi A, Contreras G, et al. A Multicenter Randomized Clinical Trial of Hemodialysis Access Blood Flow Surveillance Compared
to Standard of Care: The Hemodialysis Access Surveillance Evaluation
(HASE) Study. Kidney Int Rep. 2020 Aug 4;5(11):1937-1944.
17. Paulson WD, Ram SJ, Work J, Conrad SA, Jones SA. Inflow stenosis
obscures recognition of outflow stenosis by dialysis venous pressure:
analysis by a mathematical model. Nephrol Dial Transplant 2008 Dec;
23(12):3966–3971. https://doi.org/10.1093/ndt/gfn400. Epub 2008
Jul 23. PMID: 18653475.
18. Fluck R, Kumwenda M. Renal Association Clinical Practice Guideline
on vascular access for haemodialysis. Nephron Clin Pract. 2011;118
(Suppl 1):c225-c240. https://doi.org/10.1159/000328071

19. Tessitore N, Lipari G, Poli A, Bedogna V, Baggio E, Loschiavo C,
Mansueto G, Lupo A Can blood flow surveillance and preemptive
repair of subclinical stenosis prolong the useful life of arteriovenous
fistulae? A randomized controlled study. Nephrol Dial Transplant. Sep
2004;19(9):2325-2333. https://doi.org/10.1093/ndt/gfh316
20. Chan KE, Pflederer TA, Steele DJ, et al. Access survival amongst
hemodialysis patients referred for preventive angiography and percutaneous transluminal angioplasty. Clin j Am Soc Nephrol: CJASN. Nov
2011;6(11):2669-2680.
21. Sun C-Y, Mo Y-W, Lan LJ, et al. It is time to implement prepump arterial pressure monitoring during hemodialysis: a retrospective multicenter study. J Vasc Access. 2020 Nov;21(6):938-944. https://doi.
org/10.1177/1129729820917266 Epub 2020 Apr 28
22. Besarab A, Sullivan KL, Ross R, Moritz M. The utility of intra-access
monitoring in detecting and correcting venous outlet stenoses prior
to thrombosis. Kidney Int. 1995;47(5):1364-1373.
23. Tasaki Y, Sueyoshi E, Takamatsu H, et al. The outcomes of carbon
dioxide digital subtraction angiography for percutaneous transluminal
balloon angioplasty of access circuits and venous routes in hemodialysis patients. Medicine (Baltimore). 2020 Sep 4;99(36):e21890.

How to cite this article: Astor BC, Hirschman K, Kennedy J,
Frinak S, Besarab A. Development and validation of a risk
score to prioritize patients for evaluation of access stenosis.
Semin Dial. 2021;1-9. doi:10.1111/sdi.13026

